User menu

Clinical practice treatment of HIV infection in children

Bibliographic reference Brichard, Bénédicte ; Van der Linden, Dimitri. Clinical practice treatment of HIV infection in children. In: European Journal of Pediatrics, Vol. 168, no. 4, p. 387-392 (2009)
Permanent URL http://hdl.handle.net/2078.1/20974
  1. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ (1999) Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health 25:316–319
  2. Blanche Stéphane, Newell Marie-Louise, Mayaux Marie-Jeanne, Dunn David T., Teglas Jean Paul, Rouzioux Christine, Peckham Catherine S., Morbidity and Mortality in European Children Vertically Infected by HIV-1 : The French Pediatric HIV Infection Study Group and European Collaborative Study, 10.1097/00042560-199704150-00008
  3. Centers for Disease Control and Prevention (CDC) (2007) Revised recommendations for HIV testing of adults, adolescents and pregnant women in health-care settings. MMWR Recomm Rep 55:1–17
  4. Centers for Disease Control and Prevention (1994) 994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 43:1–10
  5. Centers for Disease Control and Prevention (2001) Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep 50:63–85
  6. Chakraborty R (2005) HIV-1 infection in children: a clinical and immunologic overview. Curr HIV Res 3:31–41
  7. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee (2008) Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 22:97–105
  8. Dao H, Mofenson LM, Ekpini R et al (2007) International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 197:S42–S55
  9. Day E, Buckberry K, Sharland MR, Chakraborty R (2008) Novel treatment options for pediatric HIV infection. Curr Opin Investig Drugs 9:170–175
  10. Durant J, Clevenbergh P, Halfon P et al (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:2195–2199
  11. Eley B (2008) Metabolic complications of antiretroviral therapy in HIV-infected children. Expert Opin Drug Metab Toxicol 4:37–49
  12. Eley B, Nuttall J (2007) Antiretroviral therapy for children: challenges and opportunities. Ann Trop Paediatr 27:1–10
  13. European Paediatric Lipodystrophy Group (2004) Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 18:1443–1451
  14. Goetghebuer T, Haelterman E, Le Chenadec J et al (2008) Early vs deferred highly active antiretroviral therapy in HIV infected infants: a European Collaborative Cohort Study. Retrovirology 5(suppl 1):O25
  15. Giaquinto C, Rampon O, Penazzato M et al (2007) Nucleoside and nucleotide reverse transcriptase inhibitors in children. Clin Drug Investig 27:509–531
  16. Gray L, Newell ML, Thorne C et al (2001) Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 108:116–122
  17. Green H, Gibb DM, Walker AS, Paediatric European Network for the Treatment of AIDS (PENTA) et al (2007) Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 21:947–955
  18. HIV Paediatric Prognostic Markers Collaborative Study (2005) Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 366:1868–1874
  19. Ikeda T, Ch’ng TW, Oleske JM (2007) Recommendations in pediatric antiretroviral therapy. Expert Opin Pharmacother 8:155–166
  20. Lujan-Zilbermann J, Rodriguez CA, Emmanuel PJ (2006) Pediatric HIV infection: diagnostic laboratory methods. Fetal Pediatr Pathol 25:249–260
  21. Luzuriaga K, McManus M, Mofenson L, PACTG 356 Investigators et al (2004) A trial of three antiretroviral regimens in HIV-1 infected children. N Engl J Med 350:2471–2480
  22. McKellar MS, Callens SF, Colebunders R (2008) Pediatric HIV infection: the state of antiretroviral therapy. Expert Rev Anti Infect Ther 6:167–180
  23. Prendergast A, Tudor-Williams G, Jeena P et al (2007) International perspectives, progress and future challenges of paediatric HIV infection. Lancet 370:68–80
  24. Resino S, Resino R, Micheloud D, Spanish Group of Paediatric HIV infection et al (2006) Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis 42:862–869
  25. Starr SE, Fletcher CV, Spector SA, PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group et al (2002) Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21:659–663
  26. Van der Linden D, Hainaut M, Goetghebuer T et al (2007) Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J 26:359–361
  27. Violari A, Cotton MF, Gibb DM et al (2008) Early antiretroviral therapy and mortality among HIV-infected infants. The CHER Study Team N Engl J Med 359:2233–2244
  28. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected children (2008) Guidelines for the use of antiretroviral gents in pediatric HIV infection and pediatric antiretroviral drug information. http://AIDSinfo.nih.gov
  29. WHO (2008) Paediatric HIV and treatment of children living with HIV. www.who.int/hiv/paediatric/en/index.html